[Drug therapy of erectile dysfunction--the current status].
In the medicinal therapy of erectile dysfunction (ED), both oral as well as local application are possible. The introduction of the PDE-5 inhibitor Sildenafil, as the first highly potent oral therapy for ED, caused dramatic changes in the diagnostic and therapeutic strategies in this area. The later PDE-5 inhibitors Tadalafil and Vardenafil show, as far as it is currently possible to judge, a similar profile to Sildenafil. The only previously available oral therapeutic, Yohimbin, plays an insignificant role, and the initial hopes for Apomorphin as an ED therapeutic have settled to a realistic level. Local application therapies have also become less important, with the intra-urethral application of PGE(1) being reduced to a few clinical indicated situations. The intra-cavernosal pharmacotherapy with PGE(1) is considered the gold standard when oral therapies do not work or can not be used.
Klinik für Urologie und Kinderurologie, Medizinische Hochschule, Hannover. schultheiss.dirk@mh-hannover.de
D
D
Schultheiss
C G
CG
Stief
D000284:Administration, Oral; D000287:Administration, Topical; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D000527:Alprostadil / Q000008:administration & dosage / Q000009:adverse effects; D001058:Apomorphine / Q000009:adverse effects / Q000627:therapeutic use; D018491:Dopamine Agonists / Q000009:adverse effects / Q000627:therapeutic use; D007172:Erectile Dysfunction / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D008297:Male; D010413:Penis / Q000098:blood supply; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D010879:Piperazines / Q000009:adverse effects / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D013739:Testosterone / Q000008:administration & dosage / Q000009:adverse effects; D014665:Vasodilator Agents / Q000009:adverse effects / Q000627:therapeutic use*; D015016:Yohimbine / Q000009:adverse effects / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D018491:Dopamine Agonists; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D015016:Yohimbine; D013739:Testosterone; D000068677:Sildenafil Citrate; D000527:Alprostadil; D001058:Apomorphine